Cimicifuga racemosa, Rhz. – SHENG MA

Cimicifuga racemosa, Rhz. – SHENG MA

Dosis: 2-8g/Tag

Cimicifuga wirkt in erster Linie stimulierend auf die Sexualhormonproduktion – ohne selbst Hormone zu enthalten.

Es wirkt gegen die Symptome des Östrogenmangels im Klimakterium, bei PMS, Angstzuständen, Depressionen, Streßempfindlichkeit, Libidomangel, Osteoporose, Harninkontinenz, Innerer Unruhe, trockener Haut und Schleimhäuten, vegetative Instabilität, schmerzhafte Verspannungen, Verdauungsschwäche, Arthrosen, Haarausfall, Arteriosklerose, Bluthochdruck, Muskelschwäche und metabolischem Syndrom.

Diese Symptome entstehen durch eine Minderung der nährenden Funktion des Östrogens. Unter dem Nährmangel leiden in erster Linie die Nervenzellen und die schnell sich teilenden Zellen.

Gleichzeitig mindert sich die Fähigkeit der Zellen Schadstoffe zu neutralisieren mit der Folge der Vermehrung von Ablagerungen von Stoffwechselprodukten, welche ihrerseits die Zelltätigkeit schädigen. Folgen sind degenerative systemische Krankheiten wie Krebs, Hyperlipidämien, Arthrosen, Alzheimer, Parkinson, Kardiomyopathien, Vermehrung von Körperfett.

 

1.      Menopause

– Efficacy of black cohosh (Cimicifuga racemosa L.) in treating early symptoms of menopause: a randomized clinical trial.

Black cohosh reduced the GCS total score and all GCS subscale scores (vasomotor, psychiatric, physical, and sexual symptoms) during 4 and 8 weeks of treatment.

– Efficacy and safety of Cimicifuga foetida extract on menopausal syndrome in Chinese women.

Cimicifuga foetida extract is effective and safe in the treatment of menopausal syndrome. It is worth extending its use in the treatment of climacteric complaints, especially among those having contradiction for hormone replacement therapy.

– The effect of a Cimicifuga racemosa extracts Ze 450 in the treatment of climacteric complaints–an observational study.

This observational study demonstrated that treatment with CR in unselected patients with climacteric complaints under the conditions of daily practice resulted in a significant improvement of menopausal symptoms

– The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa).

In postmenopausal women CR BNO 1055 reduced major climacteric complaints as effectively as conjugated estrogens and significantly more than placebo. The effective compounds in CR are most likely neurotransmitter-mimetic in nature: dopaminergic, noradrenergic, serotoninergic. We conclude that CR extracts at low doses are effective to ameliorate climacteric complaints but are devoid of adverse estrogenic effects.

2. PMS

Assessment report on Cimicifuga racemosa (L.) Nutt., rhizoma

In Germany Cimicifuga has been used since 1940 as a natural agent for treating premenstrual, dysmenorrhoeal and menopausal neurovegetative symptoms. Nowadays only menopausal neurovegetative symptoms (such as hot flushes and profuse sweating) are accepted as indications.

3. Osteoporose

– Effects of remifemin treatment on bone integrity and remodeling in rats with ovariectomy-induced osteoporosis

The preventive effects of Remifemin against bone-loss can rival those of estradiol valerate if treatment duration is adequately extended. In conclusion, Remifemin may demonstrate equivalent effects to estradiol valerate in terms of preventing postmenopausal osteoporosis.

– Effects of Remifemin Treatment on Bone Integrity and Remodeling in Rats with Ovariectomy-Induced Osteoporosis

The preventive effects of Remifemin against bone-loss can rival those of estradiol valerate if treatment duration is adequately extended. In conclusion, Remifemin may demonstrate equivalent effects to estradiol valerate in terms of preventing postmenopausal osteoporosis.

4. Polycystisches ovarielles Syndrom

Role of phyto-oestrogens in ovulation induction in women with polycystic ovarian syndrome.

Following treatment, significant favourable changes in LH level and FSH/LH ratio (p=0.007 and 0.06, respectively) were seen in the Klimadynon group. In this group the progesterone level was higher from the first treatment cycle, indicating better ovulation (p=0.0001), and endometrial thickness was greater (p=0.0004). The pregnancy rate was higher in the Klimadynon group but the difference between the groups was not significant (p=0.1)

5. Harninkontinenz

– Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness

W0200236140A revealed that the presence of Cimicifuga preparations of urinary incontinence are therapeutically effective.

– Verwendung einer zubereitung von cimicifuga racemosa

Eine Zubereitung aus Cimicifuga racemosa lässt sich erfolgreich zur Behandlung der Harninkontinenz bei weiblichen Säugetieren nach einer Ovario-Hysterektomie einsetzen. Positive Ergebnisse sind auch für die Behandlung von Frauen nach einer Hysterektomie bzw. nach der Menopause zu erwarten.

6. Metabolisches Syndrom

– Cimicifuga racemosa and its triterpene-saponins prevent the Metabolic Syndrome and deterioration of cartilage in the knee joint of ovariectomized rats by similar mechanisms.

Therefore, increased fat tissue in joints appears to belong to the Metabolic Syndrome. This effect can be largely prevented by CR BNO 1005 and its S- but not by its R-fraction. Hence, the saponins in CR BNO 1055 may be useful in preventing the Metabolic Syndrome and osteoarthritis.

– Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness

Medicament according to one of the preceding claims wherein the application is selected from metabolic syndrome, hypercholesterolemia, arteriosclerosis, heart attack, type II diabetes, obesity, in particular, android obesity, visceral fat, particularly visceral fat in the joint, in the muscle in the abdominal cavity.

6.1.    Bauchfett/Übergewicht

– Cimicifuga racemosa and its triterpene-saponins prevent the Metabolic Syndrome and deterioration of cartilage in the knee joint of ovariectomized rats by similar mechanisms.

The special extract of Cimicifuga racemosa CR BNO 1055 was shown to reduce the size of the abdominal fat depot

– – Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness

Medicament according to one of the preceding claims wherein the application is selected from metabolic syndrome, hypercholesterolemia, arteriosclerosis, heart attack, type II diabetes, obesity, in particular, android obesity, visceral fat, particularly visceral fat in the joint, in the muscle in the abdominal cavity.

6.2.    Diabetes

Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice.

In summary, the results demonstrate that Ze 450 reduced significantly body weight, plasma glucose, improved glucose metabolism and insulin sensitivity in diabetic ob/ob mice. In vitro experiments suggest that part of the effects may be related to AMPK activation.

7. Krebs

7.1.    Prostatakrebs

Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055

Collectively, these data show for the first time that the anti-proliferative effects of BNO-1055 result from hindered nucleoside uptake due to impaired ENT activity and demonstrate the potential therapeutic use of BNO-1055 for modulation of nucleoside transport.

7.2.    Brustkrebs

Treating oestrogen-dependent tumour with Cimicifuga racemosa extract

The effect of the invention of Cimicifuga extract on the proliferation of estrogen-dependent cancer cells, in particular breast cancer cells, is carried out in vitro with a test system of MCF-7 cells.

8. Depressionen

Antidepressant-like effects of the extract from Cimicifuga foetida L.

XMT significantly reduced immobility duration in FST and TST without affecting locomotor activity, increased swimming and climbing durations in FST, and enhanced 5-HTP-induced head-twitch response while did not affect yohimbine-induced lethality in female mice. XMT also normalized the inhibition of sucrose intake and decreased the levels of plasma adrenocorticotropic hormone and serum corticosterone and adrenal gland weight in CMS-treated female rats.

9. Stress

Oral administration of Cimicifuga racemosa extract attenuates psychological and physiological stress responses.

Treatment with CR significantly attenuated the elevated subjective perception of stress and the increased salivary chromogranin-A levels compared with placebo treatment.

10. Arthrose

– Cimicifuga racemosa and its triterpene-saponins prevent the Metabolic Syndrome and deterioration of cartilage in the knee joint of ovariectomized rats by similar mechanisms.

The fat load in the knee joint correlated inversely with the size of knee cartilage tissue.

– Aqueous extracts of Cimicifuga racemosa and phenolcarboxylic constituents inhibit production of proinflammatory cytokines in LPS-stimulated human whole blood.

The effect of this compound may explain the antiinflammatory activities of CRE and its beneficial actions in rheumatism and other inflammatory diseases.

11. Muskelschwäche

Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness

Medicines containing Cimicifuga for use in preventing muscle weakness or muscle weakness, especially muscle weakness of striated muscles.

12. Arteriosklerose

Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness

Furthermore, in WO1999047149A1 the suitability of Cimicifuga extracts for the treatment of osteoporosis and arteriosclerosis are disclosed.

13. Herzinsuffizienz

Medicine containing Cimicifuga for use in the treatment of sarcopenia and myocardial weakness

Furthermore, the cross sections of the muscle fibers of the heart of rats were also studied. It was found that the cross-sections of the muscle fibers of the heart are significantly larger than the knockout animals. Also speaks for the increase in the force of the heart by Cimicifuga.

Monographien

http://www.chiro.org/nutrition/ABSTRACTS/What_is_Black_Cohosh.shtml

 

TCM

Die 5-Elementeanalyse bildet die Energiedynamik von Rhz. Cimicifugae wie folgt ab:

Blau bedeutet :  Phytotherapiequellen

Grün bedeutet:  Phytotherapiequellenn und Studien

Schwarz :           Studien

Rot:                    Studien Hauptwirkung

 

Zum Verständnis der Abkürzungen des Schaubildes siehe

Struktur – und Wandlungsmodell der chinesischen Medizin

http://www.chinesischemedizin.com/CMS/index.php/struktur-und-wandlungsmodell.h